<DOC>
	<DOCNO>NCT02131272</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety insulin detemir versus insulin Neutral Protamine Hagedorn ( NPH ) combination maximum tolerate dose metformin diet/exercise glycaemic control child adolescent type 2 diabetes insufficiently control maximum tolerate dose metformin without oral antidiabetic drug ( ) without basal insulin .</brief_summary>
	<brief_title>A Trial Investigating Efficacy Safety Insulin Detemir Versus Insulin NPH Combination With Metformin Diet/Exercise Children Adolescents With Type 2 Diabetes Insufficiently Controlled Metformin With Without Other Oral Antidiabetic Drug ( ) With Without Basal Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Informed consent subject legally acceptable representative ( LAR ) child assent subject obtain trialrelated activities.Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , equal 10 year equal 17 year time signing inform consent/assent Diagnosis type 2 diabetes mellitus least 3 month prior screen Treated maximum tolerated stable dose metformin least 3 month prior screen document complete metformin intolerance HbA1c ( glycosylated haemoglobin ) equal 7.0 % equal 10.5 % ( equal 53 mmol/mol equal 91 mmol/mol ) screen Maturity onset diabetes young ( MODY ) Fasting Cpeptide screen 0.6 ng/mL Impaired liver function define alanine aminotransferase ( ALT ) equal 2.5 time upper normal limit Known proliferative retinopathy maculopathy require acute treatment judge investigator Treatment medication indication diabetes obesity state inclusion criterion period 3 month day screen</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>